ANKRD50

Across TCGA pan-cancer cohorts, ANKRD50 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ANKRD50 data layer compared with 21 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher ANKRD50 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated ANKRD50 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCEC, ACC, and KIRC are the cancer types where ANKRD50 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	0.941	0.600	.001	36	view →
ACC	OS	Median	All	0.273	0.802	.017	15	view →
KIRC	OS	Median	All	0.127	0.874	<.001	12	view →
READ	DFS	Median	All	0.138	0.731	<.001	12	view →
TGCT	DFS	Median	All	0.542	0.842	.014	6	view →
ESCA	DFS	Median	II,III,IV	0.208	0.527	.027	6	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ANKRD50–UCEC (DFS)

Open the UCEC breakdown →